---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038981"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:13:18.359699+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule

## Summary
- Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.
- GAAP net loss $60M, improved from $217M YoY; Adjusted EBITDA -$28M, up from -$99M.
- Achieved $250M annualized cost reduction target three months ahead of schedule.
- Cash, equivalents, marketable securities $474M as of June 30, 2025.
- Reaffirmed FY2025 total revenue outlook $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.

## SEC filing metadata
- accession: 0001628280-25-038981
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/0001628280-25-038981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/dna-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038981
- JSON: https://secwatch.observer/filing/0001628280-25-038981.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.